Malcisbo

Switzerland
Schlieren, Zurich, Switzerland, CH-8952

Company profile

Malcisbo company profile

Malcisbo develops novel carbohydrate-based vaccines for human and animal health. Their focus is on parasitic diseases, on human food safety and on zoonotic diseases. The company has developed its proprietary target discovery platform to identify carbohydrates as vaccine targets. Combined with their glycoengineering technologies, novel and efficient glycoconjugate vaccines are being developed. Malcisbo is developing a strong pipeline of novel vaccine products coming out this platform for unmet needs in human and veterinary medicine targeting large markets. It is Malcisbo’s goal to develop affordable vaccines to protect people in underdeveloped areas against parasitic worm infections (e.g., helminthic infections by hookworm, filaria or schistosoma).

Business identity

Contact email
[email protected]
Phone number
41 44 633 78 87
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2010-01-01, Year

Headquarters

Postal code
CH-8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
2
Total equity funding
$94,751
Last funding
Pre Seed / $94,751 / 2010-07-07
Last equity funding
Pre Seed / $94,751
Investors
1
Lead investors
1
Articles
1

Founders and investors

Lead investors

Venture Kick

Investors

Venture Kick